RhumbLine Advisers’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-124,022
| Closed | -$2.23M | – | 3077 |
|
|
2020
Q2 | $2.23M | Buy |
124,022
+14,387
| +13% | +$200K | ﹤0.01% | 1669 |
|
|
2020
Q1 | $782K | Buy |
109,635
+1,171
| +1% | +$14.6K | ﹤0.01% | 1988 |
|
|
2019
Q4 | $2.59M | Buy |
108,464
+9,601
| +10% | +$265K | ﹤0.01% | 1658 |
|
|
2019
Q3 | $2.65M | Buy |
98,863
+6,426
| +7% | +$180K | ﹤0.01% | 1574 |
|
|
2019
Q2 | $2.51M | Buy |
92,437
+5,442
| +6% | +$171K | ﹤0.01% | 1600 |
|
|
2019
Q1 | $3.02M | Sell |
86,995
-967
| -1% | -$27.9K | 0.01% | 1472 |
|
|
2018
Q4 | $1.72M | Buy |
87,962
+28,632
| +48% | +$589K | ﹤0.01% | 1732 |
|
|
2018
Q3 | $1.58M | Sell |
59,330
-3,730
| -6% | -$122K | ﹤0.01% | 1778 |
|
|
2018
Q2 | $2.38M | Buy |
63,060
+8,948
| +17% | +$342K | ﹤0.01% | 1578 |
|
|
2018
Q1 | $1.77M | Sell |
54,112
-770
| -1% | -$33.8K | ﹤0.01% | 1677 |
|
|
2017
Q4 | $2.67M | Sell |
54,882
-9,807
| -15% | -$496K | 0.01% | 1458 |
|
|
2017
Q3 | $3.5M | Buy |
64,689
+7,210
| +13% | +$423K | 0.01% | 1254 |
|
|
2017
Q2 | $3.23M | Sell |
57,479
-670
| -1% | -$26.8K | 0.01% | 1272 |
|
|
2017
Q1 | $2.28M | Buy |
58,149
+3,097
| +6% | +$98.6K | 0.01% | 1475 |
|
|
2016
Q4 | $1.24M | Buy |
55,052
+1,411
| +3% | +$27.6K | ﹤0.01% | 1739 |
|
|
2016
Q3 | $1.22M | Sell |
53,641
-350
| -0.6% | -$8.21K | ﹤0.01% | 1709 |
|
|
2016
Q2 | $1.27M | Buy |
53,991
+2,041
| +4% | +$50.4K | ﹤0.01% | 1638 |
|
|
2016
Q1 | $1.06M | Buy |
51,950
+2,580
| +5% | +$81.9K | ﹤0.01% | 1750 |
|
|
2015
Q4 | $2.54M | Buy |
49,370
+7,075
| +17% | +$343K | 0.01% | 1200 |
|
|
2015
Q3 | $1.8M | Sell |
42,295
-100
| -0.2% | -$4.83K | 0.01% | 1387 |
|
|
2015
Q2 | $1.93M | Buy |
42,395
+1,645
| +4% | +$66.2K | 0.01% | 1435 |
|
|
2015
Q1 | $1.55M | Buy |
40,750
+7,695
| +23% | +$264K | ﹤0.01% | 1569 |
|
|
2014
Q4 | $936K | Buy |
33,055
+3,530
| +12% | +$98.1K | ﹤0.01% | 1862 |
|
|
2014
Q3 | $746K | Sell |
29,525
-1,200
| -4% | -$31.6K | ﹤0.01% | 1953 |
|
|
2014
Q2 | $897K | Buy |
30,725
+22,544
| +276% | +$546K | ﹤0.01% | 1900 |
|
|
2014
Q1 | $212K | Sell |
8,181
-470
| -5% | -$12.5K | ﹤0.01% | 2738 |
|
|
2013
Q4 | $223K | Buy |
8,651
+210
| +2% | +$5.1K | ﹤0.01% | 2764 |
|
|
2013
Q3 | $226K | Sell |
8,441
-9
| -0.1% | -$214 | ﹤0.01% | 2711 |
|
|
2013
Q2 | $208K | Buy |
+8,450
| New | +$168K | ﹤0.01% | 2960 |
|
RhumbLine Advisers's PTLA Position: Q3 2020 in Review
RhumbLine Advisers sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 124,022 shares — an estimated $2.23M sold.
RhumbLine Advisers first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $3.5M in Q3 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- RhumbLine Advisers reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- RhumbLine Advisers sold 124,022 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $2.23M.
- RhumbLine Advisers first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- RhumbLine Advisers's Portola Pharmaceuticals, Inc. position peaked at $3.5M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on RhumbLine Advisers's 13F filing for Q3 2020, filed 12 Nov 2020.